Clinical Report: Neoadjuvant Chemoimmunotherapy Results in Complete Pathological Response

Overview

This report presents two cases of patients with stage III EGFR-mutant NSCLC who achieved complete pathological response following neoadjuvant chemoimmunotherapy. Both patients exhibited high PD-L1 levels, which may enhance treatment efficacy, and had previously failed targeted therapy, suggesting a potential new strategy for this subset of patients.

Background

EGFR-mutant non-small cell lung cancer (NSCLC) poses unique treatment challenges due to an immunosuppressive tumor microenvironment and frequent exclusion from clinical trials. Understanding the efficacy of neoadjuvant chemoimmunotherapy in this context is crucial for improving treatment outcomes.

Data Highlights

No numerical data or trial data was provided in the source material.

Key Findings

• Two patients with stage IIIA EGFR-mutant NSCLC and high PD-L1 expression achieved pathological complete response after neoadjuvant chemoimmunotherapy.
• Case 1 received pemetrexed, carboplatin, and pembrolizumab, while Case 2 received pemetrexed, carboplatin, and sintilimab.
• Both patients remained disease-free after 16 and 22 months of follow-up, respectively.
• These cases suggest that neoadjuvant chemoimmunotherapy may be effective for EGFR-mutant NSCLC patients with high PD-L1 expression.
• Validation through larger, prospective clinical trials is necessary to confirm these findings.

Clinical Implications

The findings indicate that neoadjuvant chemoimmunotherapy could be a viable treatment option for select patients with EGFR-mutant NSCLC who exhibit high PD-L1 levels and have failed targeted therapies. Clinicians should consider this approach cautiously while awaiting further validation from larger studies.

Conclusion

Neoadjuvant chemoimmunotherapy may offer a promising strategy for achieving complete pathological responses in specific EGFR-mutant NSCLC patients, highlighting the need for further research in this area.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Source, Year -- Title
3. Author(s)/Org, Source, Year -- Title
4. Author(s)/Org, Source, Year -- Title
5. Author(s)/Org, Source, Year -- Title
6. Author(s)/Org, Source, Year -- Title
7. Author(s)/Org, Source, Year -- Title
8. Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer | New England Journal of Medicine
9. Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA. | Journal of Clinical Oncology
10. Hope and Challenges: Immunotherapy in EGFR-Mutant NSCLC Patients - PMC